Rani Therapeutics (NASDAQ:RANI – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Insider and Institutional Ownership
30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Rani Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Entrada Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Rani Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 1,040.81%. Entrada Therapeutics has a consensus price target of $17.75, suggesting a potential upside of 173.08%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Rani Therapeutics is more favorable than Entrada Therapeutics.
Valuation & Earnings
This table compares Rani Therapeutics and Entrada Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rani Therapeutics | $1.63 million | 65.59 | -$29.67 million | ($0.27) | -2.84 |
| Entrada Therapeutics | $25.42 million | 9.96 | -$143.75 million | ($3.96) | -1.64 |
Rani Therapeutics has higher earnings, but lower revenue than Entrada Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Rani Therapeutics and Entrada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
| Entrada Therapeutics | -3,537.73% | -57.61% | -46.54% |
Summary
Rani Therapeutics beats Entrada Therapeutics on 9 of the 14 factors compared between the two stocks.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
About Entrada Therapeutics
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
